We describe the t(8;21) AML sub-type and its clinical manifestations, how its structure and biochemistry differs from that of RUNX1 and how it serves as a paradigm for the in-depth analysis of AML subtypes. Here, RUNX1 is linked to acute myeloid leukemia.